๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pardoprunox performs well in early Parkinson's disease

Book ID
120844460
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2008
Weight
139 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pardoprunox in early Parkinson's disease
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials
โœ Cristina Sampaio; Juliana Bronzova; Robert A. Hauser; Anthony E. Lang; Olivier R ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 224 KB ๐Ÿ‘ 1 views

## Abstract This report presents the results of 2 randomized trialsโ€”Rembrandt and Vermeerโ€”on the efficacy and safety of pardoprunox in patients with early Parkinson's disease. Patients with Parkinson's disease with a Unified Parkinson's Disease Rating Scaleโ€“Motor score โ‰ฅ 10 and modified Hoehn and Y

Double-blind study of pardoprunox, a new
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
โœ Juliana Bronzova; Cristina Sampaio; Robert A. Hauser; Anthony E. Lang; Olivier R ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 1 views

## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o

Early Parkinsonโ€™s Disease
Early Parkinsonโ€™s Disease
โœ Anna H. Hristova, Dr William C. Koller ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Springer International Publishing AG ๐ŸŒ English โš– 241 KB